» Articles » PMID: 37674644

Characteristics Associated with Survival in Patients Receiving Continuous Deep Sedation in a Hospice Care Unit

Overview
Date 2023 Sep 7
PMID 37674644
Authors
Affiliations
Soon will be listed here.
Abstract

Continuous deep sedation (CDS) is an extreme form of palliative sedation to relieve refractory symptoms at the end of life. In this study, we shared our experiences with CDS and examined the clinical characteristics associated with survival in patients with terminal cancer who received CDS. We conducted a chart audit of 106 consecutive patients with terminal cancer who received CDS at a single hospice care unit between January 2014 and December 2016. Survival was defined as the first day of admission to the date of death. The associations between clinical characteristics and survival were presented as hazard ratios and 95% confidence intervals using a Cox proportional hazard model. The mean age of participants was 65.2 years, and 33.0% (n=35) were women. Diazepam was the most commonly administered drug, and haloperidol or lorazepam were also used if needed. One sedative was enough for a majority of the patients. Stepwise multivariate analysis identified poor functioning, a high Palliative Prognostic Index score, hyperbilirubinemia, high serum ferritin levels, and a low number of sedatives as independent poor prognostic factors. Our experiences and findings are expected to be helpful for shared decision-making and further research on palliative sedation.

References
1.
Maltoni M, Pittureri C, Scarpi E, Piccinini L, Martini F, Turci P . Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol. 2009; 20(7):1163-9. DOI: 10.1093/annonc/mdp048. View

2.
Shin J, Chang Y, Park S, Choi J, Kim S, Choi Y . Clinical Practice Guideline for Care in the Last Days of Life. Hanguk Hosupisu Wanhwa Uiryo Hakhoe Chi. 2023; 23(3):103-113. PMC: 10332720. DOI: 10.14475/kjhpc.2020.23.3.103. View

3.
Gu X, Cheng W, Chen M, Liu M, Zhang Z . Palliative sedation for terminally ill cancer patients in a tertiary cancer center in Shanghai, China. BMC Palliat Care. 2015; 14:5. PMC: 4373517. DOI: 10.1186/s12904-015-0002-6. View

4.
Won Y, Chun H, Seo M, Kim R, Kim J, Kang J . Clinical Patterns of Continuous and Intermittent Palliative Sedation in Patients With Terminal Cancer: A Descriptive, Observational Study. J Pain Symptom Manage. 2019; 58(1):65-71. DOI: 10.1016/j.jpainsymman.2019.04.019. View

5.
Bodnar J . A Review of Agents for Palliative Sedation/Continuous Deep Sedation: Pharmacology and Practical Applications. J Pain Palliat Care Pharmacother. 2017; 31(1):16-37. DOI: 10.1080/15360288.2017.1279502. View